Resistance to epinephrine and hypersensitivity (hyperresponsiveness) to CB1 antagonists in a patient with pseudohypoparathyroidism type Ic.
Pseudohypoparathyroidism (PHP) covers a heterogeneous group of disorders, which have in common resistance to parathyroid hormone (PTH). However, they differ in many aspects such as site of the defect in signal transduction, clinical picture (with or without Albright's hereditary osteodystrophy (AHO)), extension of hormone resistance, and the tissue activity of protein Gs. PHP type Ic, a rare subtype, is characterized by resistance to several hormones, the presence of AHO, and normal activity of protein Gs. We present the case of a patient with PHP type Ic. Although resistance to TSH was suggested at the age of 12 months, diagnosis was made when she presented with hypocalcemia and resistance to PTH. Resistance to GH was also detected, and partial resistance to gonadotropins became clear after puberty. We demonstrated a defective lipolytic response to epinephrine, suggesting a role of this resistance in the pathogenesis of her morbid obesity. In view of the difficulties in the management of overweight in this disorder, treatment with a cannabinoid receptor type 1 (CB1) antagonist was started, and it proved to be highly effective, lowering the patient's body mass index from 40.5 to 33.5, which was quite impressive. We propose that an underactive melanocortin-4 receptor, which is found in certain patients with PHP, leads to upregulation of the CB1 receptor and consequently to a good response to treatment with CB1 antagonists. Another interesting finding was the GNAS mutation that was identified in this patient. A nonsense mutation resulted in a truncated Gsa that was able to stimulate adenylyl cyclase efficiently, but could not bind to receptors in a normal way.
Al-Salameh
Abdallah
A
Hospitalisation de Semaine, CHRU Bretonneau, 2 bis Boulevard Tonnellé, 37044 Tours Cedex 9, France.
Despert
F
F
Kottler
Marie-Laure
ML
Linglart
Agnès
A
Carel
Jean-Claude
JC
Lecomte
Pierre
P
D000328:Adult; D002186:Cannabinoids / Q000037:antagonists & inhibitors*; D018389:Codon, Nonsense; D004837:Epinephrine; D005260:Female; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000235:genetics / Q000378:metabolism; D006801:Humans; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011547:Pseudohypoparathyroidism / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D000077285:Rimonabant
D002186:Cannabinoids; D018389:Codon, Nonsense; D010880:Piperidines; D011720:Pyrazoles; D019205:GTP-Binding Protein alpha Subunits, Gs; D000077285:Rimonabant; D004837:Epinephrine